Key Highlights

  • The stock rose 13.21% to USD 0.6102 in regular trading on November 3, 2026, up USD 0.0712.
  • Second quarter Revenue was USD 1.771 million, down 0.4% from USD 1.778 million a year earlier.
  • The second quarter net loss was USD 14.324 million, or USD 0.17 per share.
  • Cash and marketable securities were USD 30.421 million at June 30, 2026.
  • Third quarter results are scheduled for November 12, 2026 at 8:30 a.m. ET.

What Moved InspireMD Today (up USD 0.0712, 13.21%)

InspireMD (NASDAQ:NSPR) rose 13.21% to USD 0.6102 in regular trading on November 3, 2026, a gain of USD 0.0712 from the Monday, November 2, 2026 close. The implied prior close is about USD 0.539 (calculated).

No company press release or regulatory filing dated between October 30 and November 3, 2026 was identified as a trigger. The most recent company notice, dated October 29, 2026, set the third quarter results date. The move looks like a bounce in a heavily sold small cap ahead of that report and of expected FDA decisions, and the company has not explained it.

What Is Driving Sentiment Around the Stock?

The central issue is the voluntary U.S. recall of the CGuard Prime 135 cm carotid stent delivery system, announced in a filing dated May 1, 2026. The company said the delivery system's technical success in carotid stenting procedures did not meet expectations during a controlled U.S. launch. The recall covers only the delivery system, not the stent implant. It also withdrew its 2026 revenue guidance.

The same filing said the FDA had approved an investigational device exemption for the CGUARDIANS III pivotal study of the SwitchGuard neuro protection system. The company has said it expects FDA decisions later this year on the CGuard Prime 80 cm stent for transcarotid artery revascularisation and on the original CGuard platform; the redesigned 135 cm system is expected to be filed before year end.

What Does InspireMD Do and How Did the Latest Quarter Look?

InspireMD develops the CGuard Prime carotid stent system for stroke prevention, using a proprietary MicroNet mesh. For the second quarter ended June 30, 2026, reported on August 17, 2026, revenue was USD 1.771 million, flat on USD 1.778 million a year earlier. International revenue rose 21% to USD 2.122 million, while U.S. revenue was negative USD 351 thousand because of USD 734 thousand in recall related customer credits.

The GAAP gross loss was USD 774 thousand, including a USD 612 thousand inventory impairment. Operating expenses were USD 13.671 million, up 2.5%. The net loss widened to USD 14.324 million from USD 13.151 million, although loss per share narrowed to USD 0.17 from USD 0.26 on a larger share count.

What Are the Balance Sheet and Listing Risks?

Cash and marketable securities fell to USD 30.421 million at June 30, 2026 from USD 54.211 million at December 31, 2025. The company expects annual savings of about USD 9 million from cost actions. Its filings list substantial doubt about its ability to continue as a Going Concern among the risk factors, and a July 23, 2026 filing reported a Nasdaq notice about the USD 1.00 minimum bid price.

As a Penny Stock trading at USD 0.6102, the shares can move sharply on thin liquidity, and further Equity raising could dilute existing holders.

What to Watch Next

The next dated event is the third quarter report on Thursday, November 12, 2026, with a call at 8:30 a.m. ET. Investors will look for cost savings, international growth and the cash balance. FDA news and any update on the Nasdaq bid price matter could also move the shares.